MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02 2024 - 7:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications and Be Biopharma (“Be Bio”),
a company pioneering the development of Engineered B Cell Medicines
(BCMs) to dramatically improve the lives of patients who are living
with genetic diseases, cancer, and other serious
conditions, today announced the signing of a strategic
platform license (SPL) to support the development of Be Bio’s BCMs
programs.
Under the terms of the agreement, Be Bio obtains non-exclusive
research, clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive annual licensing fees and
program-related revenue.
“We are thrilled to support Be Bio’s pioneering efforts in the
creation of Engineered B Cell Medicines (BCMs),” said Maher Masoud,
President and CEO of MaxCyte. “Our technology and expertise will
empower them to unlock the potential of human B cells to address
the unmet medical needs of patients with genetic diseases, cancer,
and beyond. This new class of therapies could be transformative,
and we are excited to be part of this journey.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of
leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Be Bio is MaxCyte’s 27th clinical/commercial
partnership overall, each of which generates pre-commercial
milestone revenue, the vast majority of which include sales-based
payments.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients’ lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today’s processes to innovate tomorrow’s
solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
About Be Biopharma
Be Biopharma (“Be Bio”) is pioneering Engineered B Cell
Medicines (BCMs) to dramatically improve the lives of patients who
are living with Hemophilia B and other genetic diseases, cancer,
and other serious conditions. With eyes locked on the patient, our
team of purpose-driven scientists, technologists, manufacturing
experts and business builders collaborate to create a bold new
class of cell therapies. Be Bio was founded in October 2020 by B
cell engineering pioneers David Rawlings, M.D., and Richard James,
Ph.D., from Seattle Children’s Research Institute. Be Bio is backed
by ARCH Venture Partners, Atlas Venture, RA Capital Management,
Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda
Ventures, Seattle Children’s Research Institute and others. Since
our founding, Be Bio’s investors have committed over $180 million
to enable the Company to re-imagine medicine based on the power of
B cell therapy. For more information, please visit us at be.bio and
our LinkedIn page.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeAnya Bolshem abolshem@spectrumscience.com +1
732-284-1751
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy CrossleyCorporate
BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserICR
ConsiliumMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Be Bio Contacts:
Investor Relationsir@be.bio
Media:media@be.bio
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From May 2024 to Jun 2024
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From Jun 2023 to Jun 2024